Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) (ORCHIDEE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02338570
Recruitment Status : Terminated (Stopped on November 16th 2016, because of recruitment failure.)
First Posted : January 14, 2015
Last Update Posted : February 5, 2018
Information provided by (Responsible Party):
Mario Negri Institute for Pharmacological Research

Brief Summary:
Evaluation of unfavourable outcome-related factors in patients affected by renal cell cancer in treatment with everolimus and previously treated with a Vascular endothelial growth factor (VEGF) inhibitor (i.e. sunitinib, sorafenib,pazopanib, or bevacizumab+interferon)

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma Drug: Everolimus Phase 4

Detailed Description:

Predictive factors to be considered are: histology, Heng risk group, Eastern Cooperative Oncology Group-performance status (ECOG-PS), site of metastases, glycemia and cholesterolemia.

The data collected in this "real life" population could contribute to identify clinical factors that predict favourable outcomes in patients treated with everolimus after failure or a a first-line treatment with a VEGF inhibitor.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor
Study Start Date : July 2015
Actual Primary Completion Date : February 2018
Actual Study Completion Date : February 2018

Arm Intervention/treatment
All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
Drug: Everolimus
Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
Other Name: Afinitor

Primary Outcome Measures :
  1. predictive factors identification [ Time Frame: 36 months ]
    To identify factors predictive of a favourable outcome, in terms of survival free from an unfavourable event, in patients treated with everolimus as second line treatment for metastatic renal cell carcinoma (mRCC). A favourable outcome is being alive and on treatment without both disease progression (according to RECIST 1.1) and HRQoL deterioration (7-point decrease from baseline evaluation on the EQ-5D VAS).

Secondary Outcome Measures :
  1. Progression free survival (PFS) of everolimus as second line treatment [ Time Frame: 36 months ]
    PFS distributions will be estimated using the Kaplan-Meier method and compared using the log-rank test.

  2. health related quality of life (HRQoL) [ Time Frame: 36 months ]
    As measured by EQ-5D questionnaire. It will be described at each time by using summary statistical measures for continuous variables

  3. drug-related toxicity [ Time Frame: 36 months ]

    assessed by the National Cancer Institute-Common Terminology Criteria for adverse events (NCI-CTCAE), version 4.03.

    The frequency of maximum toxicity grade experienced by each patient for each specific toxicity will be presented as well as the frequency of patients experiencing grade 3 or 4 (grade 2 for neurotoxicity) events, and SADRs.

  4. compliance [ Time Frame: 36 months ]
    Treatment compliance will be assessed by evaluating the dose intensity (total dose divided by duration of exposure to treatment in weeks), and calculating the frequencies and proportion of patients who modified or interrupted the treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, aged 18 years or older, with histologically or cytologically confirmed mRCC (clear cell or not clear cell);
  2. ECOG-PS 0-1-2;
  3. With target and/or non-target lesions according to Response Evaluation Criteria In Solid Tumours (RECIST) 1.1;
  4. Following failure of a previous treatment with VEGF-targeted therapy (e.g. sunitinib, sorafenib, pazopanib, or bevacizumab+interferon);
  5. For whom a decision has been taken to initiate everolimus treatment or patient currently receiving treatment with everolimus by a period of time ≤30 days;
  6. Willing and able to comply with follow-up and all other protocol requirements and able to commence treatment within 21 days;
  7. Written informed consent obtained before any screening procedure and according to local guidelines.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry:

  1. Previous treatment with everolimus or at the date of written informed consent provision receiving everolimus by more than 30 days;
  2. Symptomatic central nervous system metastases. Patients may be eligible if the central nervous system metastases have been adequately treated (surgery or radiotherapy), and do not require ongoing corticosteroids for control of symptoms and have had no evidence of progression for at least three months;
  3. Other malignancy diagnosed within the last 5 years, except the following, if adequately treated: superficial squamous cell carcinoma or basal cell carcinoma of skin, superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer;
  4. Treatment with an investigational agent in the past 4 weeks;
  5. Clinically relevant human immunodeficiency virus, hepatitis B virus, hepatitis C virus infection;
  6. Non adequate liver function as shown by:

    • serum or plasma ALT and AST >3.0x upper limit of normal (ULN) >5 if hepatic metastases are present;
    • Serum or plasma total bilirubin: >1.5xULN (excepted for patients with Gilbert's syndrome);
  7. Non adequate renal function as shown by serum creatinine >2.5xULN;
  8. Any of the following in the last year: myocardial infarction, severe/ unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack or pulmonary embolism;
  9. Ongoing grade ≥2 cardiac dysrhythmias, atrial fibrillation of any grade or prolongation of the corrected QT interval to >450 msec for males or >470 msec for females;
  10. Pregnancy (negative pregnancy test required for women of child-bearing potential), breast feeding;
  11. Inadequate contraception. Women must be post-menopausal, surgically sterile, or use a reliable form of contraception. Men must be surgically sterile or use a barrier method of contraception;
  12. Known allergy or hypersensitivity to everolimus or its excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02338570

Layout table for location information
Spedali Civili
Brescia, Italy
Ospedale A Perrino
Brindisi, Italy
Istituto Europeo di Oncologia
Milano, Italy
Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale
Napoli, Italy
AOU Maggiore della Carità
Novara, Italy
Casa di Cura La Maddalena
Palermo, Italy
Unicampus Biomedico
Roma, Italy
AOU San Giovanni di Dio e Ruggi D'Aragona
Salerno, Italy
Sponsors and Collaborators
Mario Negri Institute for Pharmacological Research
Layout table for investigator information
Principal Investigator: Giacomo Cartenì Azienda Ospedaliera "Antonio Cardarelli", Napoli

Layout table for additonal information
Responsible Party: Mario Negri Institute for Pharmacological Research Identifier: NCT02338570    
Other Study ID Numbers: IRFMN-RCC-6691
First Posted: January 14, 2015    Key Record Dates
Last Update Posted: February 5, 2018
Last Verified: November 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents